Journal article

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, Jeeyun Lee, Sabine Tejpar, Andrea Sartore-Bianchi, Jaclyn F Hechtman, Jason Christiansen, Luca Novara, Niall Tebbutt, Giovanni Fuca, Carlotta Antoniotti, Seung Tae Kim, Danielle Murphy, Rosa Berenato, Federica Morano, James Sun, Bosun Min, Philip J Stephens, Marissa Chen Show all

Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2017


Background: ALK, ROS1, and NTRK fusions occur in 0.2% to 2.4% of colorectal cancers. Pioneer cases of metastatic colorectal cancer (mCRC) patients bearing rearrangements who benefited from anti-ALK, ROS, and TrkA-B-C therapies have been reported previously. Here we aimed at characterizing the clinical and molecular landscape of ALK, ROS1, and NTRK rearranged mCRC. Methods: Clinical features and molecular characteristics of 27 mCRC patients bearing ALK, ROS1, and NTRK rearranged tumors were compared with those of a cohort of 319 patients not bearing rearrangements by means of Fisher's exact, χ2 test, or Mann-Whitney test as appropriate. Overall survival curves were estimated with the Kaplan-M..

View full abstract

University of Melbourne Researchers


Awarded by AIRC IG

Awarded by Associazione Italiana per la Ricerca sul Cancro (AIRC)

Awarded by European Community

Funding Acknowledgements

This work was supported by Fondazione Associazione Ricerche e Cure in Oncologia (ARCO), Italy, and partly supported by grants AIRC IG No. 17707 (FDN); AIRC IG No. 16788 (AB); Fondo per la Ricerca Locale (ex 60%), Universita di Torino, 2014 (FDN); and Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (AB). Investigators at Niguarda Cancer Center are supported by the following grants: Terapia Molecolare dei Tumori (ASB, SS) and Dynamic of Tumor Evolution and Therapy (ASB) from Fondazione Oncologia Niguarda Onlus; Associazione Italiana per la Ricerca sul Cancro (AIRC) 2010 Special Program Molecular Clinical Oncology 5x1000, project 9970 (SS, AB); European Community's grant agreement No. 635342-2 MoTriColor (AB, SS).